New Ray Medicine International Holding Limited (HKG:6108)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.200
0.00 (0.00%)
At close: Apr 29, 2026
-56.52%
Market Cap 40.12M
Revenue (ttm) 130.37M
Net Income (ttm) -20.07M
Shares Out 200.62M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,000
Average Volume 152,696
Open 0.200
Previous Close 0.200
Day's Range 0.200 - 0.200
52-Week Range 0.191 - 0.490
Beta -4.01
RSI 43.19
Earnings Date May 8, 2026

About HKG:6108

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. The company’s pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor rel... [Read more]

Sector Healthcare
Founded 2001
Employees 31
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6108
Full Company Profile

Financial Performance

In 2025, HKG:6108's revenue was 130.37 million, an increase of 38.78% compared to the previous year's 93.95 million. Losses were -20.07 million, -35.29% less than in 2024.

Financial Statements

News

There is no news available yet.